منابع
1. Tali, T.A., et al., Epidemiology and outcome of glioblastoma multiforme: A tertiary care experience. Asian Journal of Oncology, 2023. 9.
2. Hanif, F., et al., Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific journal of cancer prevention: APJCP, 2017. 18(1): p. 3.
3. Aldoghachi, A.F., et al., Recent advances in the therapeutic strategies of glioblastoma multiforme. Neuroscience, 2022. 491: p. 240-270.
4. Zemskova, O., et al., Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma. Anticancer Research, 2024. 44(7): p. 3059-3066.
5. Burton, E., et al., A Surveillance, Epidemiology and End Results-Medicare data analysis of elderly patients with glioblastoma multiforme: Treatment patterns, outcomes and cost. Mol Clin Oncol, 2015. 3(5): p. 971-978.
6. Chow, D., et al., Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. American Journal of Roentgenology, 2017. 210(1): p. 30-38.
7. Frank, S., et al., Metastatic glioblastoma cells use common pathways via blood and lymphatic vessels. Neurol Neurochir Pol, 2009. 43(2): p. 183-90.
8. Rich, J.N., et al., Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res, 2005. 65(10): p. 4051-8.
9. Li, P. and M. Wu, Epigenetic Mechanisms of Glioblastoma, in Glioblastoma, S. De Vleeschouwer, Editor. 2017, Codon Publications
Copyright: The Authors.: Brisbane (AU).
10. Rich, J.N., et al., Gene expression profiling and genetic markers in glioblastoma survival. Cancer research, 2005. 65(10): p. 4051-4058.
11. Kloosterhof, N.K., et al., Molecular subtypes of glioma identified by genome‐wide methylation profiling. Genes, Chromosomes and Cancer, 2013. 52(7): p. 665-674.
12. Wick, W. and M. Platten, Understanding and treating glioblastoma. Neurologic clinics, 2018. 36(3): p. 485-499.
13. Dawson, M.A., The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science, 2017. 355(6330): p. 1147-1152.
14. Cheng, Y., et al., Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal transduction and targeted therapy, 2019. 4(1): p. 62.
15. Tang, Y., et al., DNA methylation-based diagnostic and prognostic biomarkers for glioblastoma. Cell Transplantation, 2020. 29: p. 0963689720933241.
16. Hahn, M.A., P.E. Szabó, and G.P. Pfeifer, 5-Hydroxymethylcytosine: a stable or transient DNA modification? Genomics, 2014. 104(5): p. 314-323.
17. Richard, S., et al., Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma. Cancer Med, 2020. 9(17): p. 6344-6353.
18. Izadpanahi, P., K. Anvari, and M. Fazl Ersi, Glioblastoma and the significance of MGMT gene methylation. Reviews in Clinical Medicine, 2014. 1(3): p. 135-140.
19. Kimura, H., Histone modifications for human epigenome analysis. Journal of Human Genetics, 2013. 58(7): p. 439-445.
20. Kim, Y.Z., Altered histone modifications in gliomas. Brain Tumor Res Treat, 2014. 2(1): p. 7-21.
21. Malzkorn, B., et al., Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol, 2011. 21(6): p. 619-32.
22. Alseksek, R.K., et al., The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention. International Journal of Molecular Sciences, 2022. 23(15): p. 8141.
23. Williams, E.A., et al., A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta Neuropathol, 2023. 146(3): p. 515-525.
24. Zang, L., et al., Potential epigenetic-based therapeutic targets for glioma. Frontiers in Molecular Neuroscience, 2018. 11: p. 408.
25. Clapier, C.R., et al., Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nature reviews Molecular cell biology, 2017. 18(7): p. 407-422.
26. Chen, H.M., et al., Roles of Chromatin Remodelling and Molecular Heterogeneity in Therapy Resistance in Glioblastoma. Cancers (Basel), 2022. 14(19).
27. Sesé, B., et al., Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology. Clinical Epigenetics, 2021. 13(1): p. 150.
28. Zhou, B., et al., Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther, 2022. 7(1): p. 95.
29. Stupnikov, M.R., et al., Jagged and Delta-like ligands control distinct events during airway progenitor cell differentiation. Elife, 2019. 8.
30. Ables, J.L., et al., Not(ch) just development: Notch signalling in the adult brain. Nat Rev Neurosci, 2011. 12(5): p. 269-83.
31. Bazzoni, R. and A. Bentivegna, Role of Notch Signaling Pathway in Glioblastoma Pathogenesis. Cancers (Basel), 2019. 11(3).
32. Jiang, L., et al., Notch1 expression is upregulated in glioma and is associated with tumor progression. Journal of Clinical Neuroscience, 2011. 18(3): p. 387-390.
33. Tsung, A.J., et al., Methylation regulates HEY1 expression in glioblastoma. Oncotarget, 2017. 8(27): p. 44398-44409.
34. Wang, H., et al., Hedgehog signaling regulates the development and treatment of glioblastoma. Oncol Lett, 2022. 24(3): p. 294.
35. Ok, C.Y., R.R. Singh, and F. Vega, Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol, 2012. 180(1): p. 2-11.
36. Sabol, M., et al., Role of GLI Transcription Factors in Pathogenesis and Their Potential as New Therapeutic Targets. Int J Mol Sci, 2018. 19(9).
37. Niewiadomski, P., et al., Gli Proteins: Regulation in Development and Cancer. Cells, 2019. 8(2).
38. Gillespie, M.S., C.M. Ward, and C.C. Davies, DNA Repair and Therapeutic Strategies in Cancer Stem Cells. Cancers (Basel), 2023. 15(6).
39. Burko, P., et al., Molecular Pathways Implicated in Radioresistance of Glioblastoma Multiforme: What Is the Role of Extracellular Vesicles? Int J Mol Sci, 2023. 24(5).
40. Zheng, Z., et al., Mechanisms and applications of radiation-induced oxidative stress in regulating cancer immunotherapy. Front Immunol, 2023. 14: p. 1247268.
41. Shrishrimal, S., E.A. Kosmacek, and R.E. Oberley-Deegan, Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis. Oxid Med Cell Longev, 2019. 2019: p. 4278658.
42. Zhou, H.M., et al., Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther, 2021. 6(1): p. 62.
43. Chu, X., et al., Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduction and Targeted Therapy, 2024. 9(1): p. 170.
44. Ramar, V., et al., Progress in Glioma Stem Cell Research. Cancers (Basel), 2023. 16(1).
45. Roy, S., et al., Hypoxic tumor microenvironment: Implications for cancer therapy. Experimental Biology and Medicine, 2020. 245(13): p. 1073-1086.
46. Ma, Z., et al., Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy. Antioxidants & redox signaling, 2021. 34(18): p. 1484-1497.
47. Agosti, E., et al., Tumor microenvironment and glioblastoma cell interplay as promoters of therapeutic resistance. Biology, 2023. 12(5): p. 736.
48. Ma, J., C.C. Chen, and M. Li, Macrophages/microglia in the glioblastoma tumor microenvironment. International journal of molecular sciences, 2021. 22(11): p. 5775.
49. Peer, E., S. Tesanovic, and F. Aberger, Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy. Cancers, 2019. 11(4): p. 538.
50. Lospinoso Severini, L., et al., The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma. Expert opinion on therapeutic targets, 2020. 24(11): p. 1159-1181.
51. Queiroz, K.C., C.A. Spek, and M.P. Peppelenbosch, Targeting Hedgehog signaling and understanding refractory response to treatment with Hedgehog pathway inhibitors. Drug Resistance Updates, 2012. 15(4): p. 211-222.
52. Rimkus, T.K., et al., Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers, 2016. 8(2): p. 22.
53. Manfreda, L., E. Rampazzo, and L. Persano, Wnt Signaling in Brain Tumors: A Challenging Therapeutic Target. Biology (Basel), 2023. 12(5).
54. Archbold, H., et al., How do they do Wnt they do?: regulation of transcription by the Wnt/β‐catenin pathway. Acta physiologica, 2012. 204(1): p. 74-109.
55. Paul, I., et al., Current understanding on EGFR and Wnt/β-catenin signaling in glioma and their possible crosstalk. Genes & cancer, 2013. 4(11-12): p. 427-446.
56. Lathia, J.D., et al., Cancer stem cells in glioblastoma. Genes & development, 2015. 29(12): p. 1203-1217.
57. Zuccarini, M., et al., The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor. Genes (Basel), 2018. 9(2).
58. El-Sehemy, A., et al., Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. J Clin Invest, 2020. 130(6): p. 3069-3086.
59. Ye, X., Y. Wang, and J. Nathans, The Norrin/Frizzled4 signaling pathway in retinal vascular development and disease. Trends in molecular medicine, 2010. 16(9): p. 417-425.
60. Kassumeh, S., S.G. Priglinger, and A. Ohlmann, Norrin mediates opposing effects on tumor progression of glioblastoma stem cells. The Journal of Clinical Investigation, 2020. 130(6): p. 2814-2815.
61. Song, H., The Role of Histone Chaperone FACT Complex in Base Excision Repair Pathway and Its Therapeutic Potential in Colon Cancer and Medulloblastoma. 2019.
62. Romani, M., M.P. Pistillo, and B. Banelli, Epigenetic targeting of glioblastoma. Frontiers in oncology, 2018. 8: p. 448.
Pathobiology Reserach